The compound exerts a novel mechanism of action by targeting isoform 2 of the translation elongation factor eEF1A (eEF1A2), which is a putative oncogene that has been shown to be upregulated in pancreatic and other cancers with expression levels that are inversely correlated with clinical outcome [16–20]. The gene discussed is EEF1A2; the disease is cancer.